Lubiprostone: viewpoints.
Schiller
Lawrence R
LR
Department of Gastroenterology, Baylor University Medical Center, Dallas, Texas, USA.
Camilleri
Michael
M
D000527:Alprostadil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000090007:CLC-2 Chloride Channels; D002400:Cathartics / Q000009:adverse effects / Q000627:therapeutic use; D065101:Chloride Channel Agonists; D018118:Chloride Channels / Q000502:physiology; D003248:Constipation / Q000188:drug therapy*; D005227:Fatty Acids / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000502:physiology; D000068238:Lubiprostone; D008297:Male
D000090007:CLC-2 Chloride Channels; D002400:Cathartics; D065101:Chloride Channel Agonists; D018118:Chloride Channels; D005227:Fatty Acids; D000068238:Lubiprostone; D000527:Alprostadil